The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| PYPD | +52.44% | -98.99% | -60.14% | -99% |
| S&P | +14.43% | +77.25% | +12.13% | +131% |
PolyPid Ltd. operates as a phase 3 biopharma company. Its proprietary PLEX technology pairs with medications, enables precise delivery of drugs at effective release rates, over pre-determined durations ranging from several days to months. The firm's product candidates are designed to address unmet medical needs by delivering active pharmaceutical ingredients, or APIs, locally at predetermined release rates and durations over extended periods ranging from days to several months. The company was founded by Noam Emanuel on February 28, 2008 and is headquartered in Petach Tikva, Israel.
No news articles found for PolyPid.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | $0.00K | 0.0% |
| Market Cap | $33.99M | 45.2% |
| Market Cap / Employee | $557.16K | 0.0% |
| Employees | 61 | 0.0% |
| Net Income | -$7,451.00K | 4.0% |
| EBITDA | -$7,386.00K | 0.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $9.86M | 98.3% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $829.00K | -79.0% |
| Short Term Debt | $3.51M | -42.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -147.37% | -14.8% |
| Return On Invested Capital | -241.46% | -53.1% |
No data available for this period.
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 9.58 | 3.59 | 418.25 | 2.55 | -75.27% |
| Price to Tangible Book Value | 9.58 | 3.59 | 418.30 | 2.55 | -75.26% |
| Enterprise Value to EBITDA | -7.07 | - | |||
| Return on Equity | -1038.7% | -853.0% | -312.8% | -390.5% | -58.59% |
| Total Debt | $9.62M | $8.83M | $8.67M | $4.34M | -56.70% |
No podcast episodes available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
